FOLR1
ENSG00000110195
Target class
Membrane receptor
Chromosome
11
Approved drugs
1
Clinical candidates (approved and in development)
4
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- Yes
- Other names
- FRα
- Target name
- FOLR1
- Gene name
- Folate receptor alpha
- Gene symbol
- FOLR1
- Previous gene symbols
- FOLR
- Protein name
- Folate receptor alpha (FR-alpha) (Adult folate-binding protein) (FBP) (Folate receptor 1) (Folate receptor, adult) (KB cells FBP) (Ovarian tumor-associated antigen MOv18)
- Gene biotype
- Protein coding
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 17
- Highest tissue expression
- 102.8
- Tissue specificity (Gini)
- 0.878
- Tissue specificity (tau)
- 0.955
- KEGG gene identifiers
- hsa:2348
- Protein interaction confidence
- 0.757833
- Protein interaction partners
- 6
- R-HSA-204005
- R-HSA-5694530
- R-HSA-6807878
- End position
- 72196323
- Start position
- 72189558
- Chromosome
- 11
- Strand
- Forward
- Cell membrane
- Lipid-anchor, GPI-anchor . Apical cell membrane
- Lipid-anchor, GPI-anchor . Basolateral cell membrane
- Lipid-anchor, GPI-like-anchor . Secreted . Cytoplasmic vesicle . Cytoplasmic vesicle, clathrin-coated vesicle . Endosome . Note=Endocytosed into cytoplasmic vesicles and then recycled to the cell membrane. .
- PubMed 2527252
- PubMed 8033114
- PubMed 8567728
- PubMed 17566972
- PubMed 7578066
- PubMed 10787414
- PubMed 3476960
- Tissue specificity (tau)
- 0.954649
- Expression inequality (Gini)
- 0.877909
Expression in transcripts per million
- Lung
- 102.8
- Minor Salivary Gland
- 72.43
- Kidney - Cortex
- 49.4
- Kidney - Medulla
- 47.69
- Thyroid
- 32.66
Expression in transcripts per million
- Lung102.8
- Minor Salivary Gland72.43
- Kidney - Cortex49.4
- Kidney - Medulla47.69
- Thyroid32.66
- Stomach10.04
- Pituitary6.72
- Fallopian Tube5.55
- Breast - Mammary Tissue2.5
- Skin - Sun Exposed (Lower leg)1.97
- Pancreas1.64
- Brain - Hippocampus1.16
- Skin - Not Sun Exposed (Suprapubic)1.16
- Prostate1.11
- Adrenal Gland1.03
- Brain - Substantia nigra1
- Nerve - Tibial1
- Brain - Hypothalamus0.89
- Brain - Spinal cord (cervical c-1)0.81
- Brain - Caudate (basal ganglia)0.79
- Brain - Nucleus accumbens (basal ganglia)0.77
- Brain - Amygdala0.69
- Cervix - Endocervix0.52
- Brain - Anterior cingulate cortex (BA24)0.49
- Testis0.4
And 29 more, listed on the interactive page.
- GO:0006898
- GO:0015884
- GO:0071231
- GO:0000139
- GO:0005634
- GO:0005768
- GO:0005789
- GO:0005886
- GO:0009897
- GO:0009986
- GO:0012507
- GO:0016020
- GO:0016323
- GO:0016324
- GO:0030133
- GO:0031410
- GO:0033116
- GO:0070062
- GO:0005515
- GO:0005542
- GO:0038023
- GO:0061714
Related records
Trials (53)
- A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
- A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα）
- A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
- A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer
- A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
- A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
- A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
- A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)
- A Study of MORAb-003 in Patients With Solid Tumor
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
- A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)
- A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
- A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- A Study to Assess Safety and Immunogenicity of Conserved Mosaic HIV-1 Vaccines
- A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
- An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Drugs (4)
- Farletuzumab Folate receptor alpha inhibitor
- Mirvetuximab Folate receptor alpha binding agent
- Mirvetuximab soravtansine Folate receptor alpha binding agent
- Vintafolide Folate receptor alpha binding agent